OraSure Technologies (NASDAQ:OSUR) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note issued to investors on Monday morning.

Separately, Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Stock Performance

Shares of OSUR opened at $4.00 on Monday. OraSure Technologies has a 52 week low of $2.08 and a 52 week high of $4.58. The firm has a market capitalization of $275.40 million, a P/E ratio of -5.80 and a beta of 1.00. The company has a 50-day simple moving average of $4.16 and a 200-day simple moving average of $3.44.

Insiders Place Their Bets

In related news, Director Steven Kyle Boyd acquired 25,000 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was bought at an average price of $2.99 per share, with a total value of $74,750.00. Following the acquisition, the director owned 113,462 shares in the company, valued at $339,251.38. This represents a 28.26% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.70% of the stock is currently owned by corporate insiders.

Institutional Trading of OraSure Technologies

Institutional investors have recently added to or reduced their stakes in the company. Amundi bought a new stake in OraSure Technologies during the first quarter worth about $47,000. AQR Capital Management LLC increased its stake in OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after acquiring an additional 339,493 shares during the last quarter. NewEdge Advisors LLC increased its stake in OraSure Technologies by 32,595.9% in the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 47,590 shares during the last quarter. Empowered Funds LLC raised its position in OraSure Technologies by 7.2% during the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after purchasing an additional 27,310 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in OraSure Technologies by 32.7% in the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 8,133 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.